-+ 0.00%
-+ 0.00%
-+ 0.00%
VibroSense Wins Australian Patent Acceptance for Chemotherapy Nerve Damage Prediction Method
Share
Listen to the news
VibroSense Wins Australian Patent Acceptance for Chemotherapy Nerve Damage Prediction Method
  • VibroSense Dynamics received a Notice of Acceptance from IP Australia for its patent application covering prediction of chemotherapy-induced peripheral neuropathy.
  • The method uses low-frequency vibration perception detection to identify patients at elevated risk of chemotherapy-related nerve damage, potentially supporting treatment adjustments.
  • Patent acceptance supports future commercialization in Australia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VibroSense Dynamics AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending